Moderna puts plans for African vaccine plant on hold Financial Times

Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges

Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine-manufacturing footprint.

Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans - Moderna (NASDAQ:MRNA)

Famed COVID-19 vaccine maker Moderna Inc (NASDAQ:MRNA) has decided to pause its plans to construct a vaccine manufacturing plant in Kenya, signaling a shift away from investing in pandemic preparedness in Africa as demand for COVID-19 vaccines wanes.  “Moderna has not received any vaccine orders for Africa since 2022 and has faced the cancellation of previous orders, resulting in more than $1 billion in losses and write-downs,” it said. Also Rea…

Moderna paused its plans for a facility in Kenya because COVID-19 vaccine demand has plummeted

Moderna said Thursday that it is pausing its plans to build an mRNA vaccine manufacturing facility in Kenya as demand for mRNA vaccines lags in Africa. The Massachusetts-based vaccine maker says the continent’s uptake of COVID-19 vaccines is no longer sufficient enough to support the project.Read more...

Moderna puts Kenya plant plans on hold

According to a statement unveiled Thursday (Apr. 11), Moderna has not received any vaccine orders for the continent since 2022 and has faced the cancellation of previous orders, resulting in more than $1 billion in losses and write-downs.

Moderna puts plans for African vaccine plant on hold Financial Times

Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline